NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $13.61 -0.26 (-1.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.72 +0.11 (+0.77%) As of 06/20/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RxSight Stock (NASDAQ:RXST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RxSight alerts:Sign Up Key Stats Today's Range$13.49▼$14.2950-Day Range$13.13▼$16.6252-Week Range$12.53▼$60.81Volume653,062 shsAverage Volume708,385 shsMarket Capitalization$553.11 millionP/E RatioN/ADividend YieldN/APrice Target$37.90Consensus RatingHold Company OverviewRxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More… RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 61% of companies evaluated by MarketBeat, and ranked 1240th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingRxSight has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 5 buy ratings, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageRxSight has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RxSight's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.70) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -20.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -20.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.66% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in RxSight has recently decreased by 2.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.66% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in RxSight has recently decreased by 2.85%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment0.98 News SentimentRxSight has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for RxSight this week, compared to 6 articles on an average week.Search Interest3 people have searched for RXST on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.57% of the stock of RxSight is held by insiders.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesRxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Hold" by BrokeragesJune 15, 2025 | americanbankingnews.comRxSight: Valuation Blowout Creates OpportunityJune 7, 2025 | seekingalpha.comAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. June 21, 2025 | Timothy Sykes (Ad)Do Options Traders Know Something About RxSight Stock We Don't?May 23, 2025 | msn.com5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)May 20, 2025 | benzinga.comRxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology ForumMay 20, 2025 | globenewswire.comRxSight, Inc. (NASDAQ:RXST) Just Reported Earnings, And Analysts Cut Their Target PriceMay 10, 2025 | finance.yahoo.comEarnings call transcript: RxSight reports Q1 2025 earnings beat, stock rises 6.67%May 9, 2025 | investing.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $34.38 on January 1st, 2025. Since then, RXST shares have decreased by 60.4% and is now trading at $13.61. View the best growth stocks for 2025 here. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). RxSight's revenue was up 28.5% compared to the same quarter last year. Read the conference call transcript. When did RxSight IPO? RxSight (RXST) raised $125 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's top institutional shareholders include Vanguard Group Inc. (5.89%), Millennium Management LLC (2.21%), Credit Agricole S A (1.93%) and T. Rowe Price Investment Management Inc. (1.77%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Ilya Goldshleger, Julie Andrews, Bakker Juliet Tammenoms, Robert Keith Warner, Tamara Fountain, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings5/07/2025Today6/21/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$37.90 High Stock Price Target$73.00 Low Stock Price Target$16.00 Potential Upside/Downside+178.5%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.45 million Net Margins-17.90% Pretax Margin-17.86% Return on Equity-9.54% Return on Assets-8.51% Debt Debt-to-Equity RatioN/A Current Ratio12.68 Quick Ratio11.65 Sales & Book Value Annual Sales$139.93 million Price / Sales3.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.98 per share Price / Book1.95Miscellaneous Outstanding Shares40,640,000Free Float36,748,000Market Cap$553.11 million OptionableOptionable Beta1.29 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:RXST) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.